Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC ...
VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in ...
Saber CEO Matthew Karch, whose company used to be part of Embracer alongside Volition, explains what happened to the defunct ...
The issues are complex, with no single causative factor. Yet central to these changes is the role of volition – human agency. Women everywhere have made and are making their own decisions about ...
Saints Row studio Volition shut down in 2023 after 30 years, leading many to wonder about the future of the open-world crime franchise. The fate of the franchise is unknown, but Saber Interactive ...
VolitionRx (VNRX) announces the results of a study which shows that an automated Nu.Q Cancer immunoassay test in development detected a range ...
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time ...
Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 ...
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung cancer primer, "Lung Cancer: Hope of a Brighter Tomorrow ...
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results